Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

2016 Annual Report: Top 10 Pipelines

The pharma industry’s R&D concentration has been shifting towards specialty therapy areas as research and development returns decline for some leaders.

Read More »

Studies find reducing sugary drinks cuts calories, but only a few

Studies from Britain and Mexico suggest reducing sugar in sweetened drinks or taxing it more to cut consumption can help people limit their calorie intake and lower their risk of developing diabetes, but not by much.   Two separate pieces of research published on Thursday in the British Medical Journal and The Lancet Diabetes & […]

Read More »

Eli Lilly’s diabetes pill takes market share from J&J, Astra

Eli Lilly and Co’s new Jardiance diabetes treatment has begun stealing market share from rival drugs in its class, the company said on Tuesday, bolstered by clinical trial data showing it slashed deaths by 32 percent in patients with Type 2 diabetes. In a three-year study whose results were released last summer, Jardiance became the […]

Read More »

Google (GOOG) Files Patent to Draw Your Blood Without Needles

MOUNTAIN VIEW, Calif. – Google Inc. is stepping closer to developing a device to draw blood for medical testing without needles, Wired reported Monday morning. The Internet giant filed a patent application Dec. 3 on a gas-based system designed to draw blood from a fingertip to be used to test blood sugar levels. According to […]

Read More »

Lilly stops development of diabetes treatment

Eli Lilly & Co said on Friday it scrapped development of an experimental diabetes treatment that had raised concerns of liver problems. Lilly had delayed applying for marketing the treatment — basal insulin peglispro — earlier in the year, after studies reported an increase in liver fat in patients. A severe buildup of fats in […]

Read More »

Amgen And Merck Announce Cancer Immunotherapy Collaboration For Patients With Non-Hodgkin Lymphoma

THOUSAND OAKS, Calif. and KENILWORTH, N.J., Dec. 4, 2015 /PRNewswire/ — Amgen (NASDAQ: AMGN) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced a cancer immunotherapy collaboration to support a Phase 1b/3 study investigating BLINCYTO® (blinatumomab) in combination with KEYTRUDA® (pembrolizumab) in patients with diffuse large B-cell lymphoma (DLBCL), which […]

Read More »

Walnuts each day keep the doctor away?

(Reuters Health) – Eating a handful of walnuts each day might help keep the doctor away, at least for some people who are at risk of developing diabetes, a U.S. study suggests. When people in the study added 56 grams of walnuts (2 ounces, or about 14 walnuts) to their daily diet for six months, […]

Read More »

Novo Nordisk A/S Breathes New Life into XOMA with $295 Million Diabetes Pact

XOMA Announces License Agreement With Novo Nordisk for XMetA Program in Diabetes Novo Nordisk acquires exclusive global rights to XMetA program for the treatment of diabetes XOMA retains commercialization rights for rare disease indications $5.0 million upfront payment Agreement includes up to $290.0 million in additional potential milestone payments XOMA is entitled to tiered royalties […]

Read More »

Exercise as young adult tied to heart health decades later

(Reuters Health) – Young adults who exercise may have a lower risk of cardiovascular disease and higher survival odds decades later than their peers who aren’t as active early in life, a U.S. study suggests. Fitness has long been linked to a reduced risk of heart disease in older adults. The new study, however, offers […]

Read More »

Beijing aims to refill medicine chest with Made in China drugs

China, already a global powerhouse in high-tech areas from solar panels to bullet trains, is turning its industrial might to the challenge of making more of its own drugs for a vast and aging population.   Given the 10 years or more it typically takes to bring a new medicine to market, original “Made in […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom